332012-41-6

Upstream product

• 123-39-7 N-Methylformamide 
• 13177-70-3 4,7-dichlorofuro[2,3-d]pyridazine 
• 4282-24-0 furan-2,3-dicarboxylic acid 
• 332013-40-8 4-chloroanilino-7-chlorofuro[2,3-d]pyridazine 
• 52900-79-5 methyl 3-methoxycarbonylfuran-2-carboxylate 
• 13177-71-4 5,6-dihydrofuro[2,3-d]pyridazine-4,7-dione 
• 488-93-7 3-Furoic acid 

Relevant academic research and scientific papers

SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY

Substituted pyridines and pyridazines having angiogenesis inhibiting activity and generalized structural formula (I) wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R and R may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes using these materials are also disclosed.

COMPOUNDS FOR TREATING PULMONARY HYPERTENSION

The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.

Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Substituted pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R1and R2may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.